Abstract
Mitochondria play a crucial role in oxidative stress control and reactive oxygen species (ROS) generation, impacting many cellular processes. Dysregulated mitochondria are linked to diseases such as colorectal cancer (CRC), known for its aggressiveness. Since ROS plays a role in tumor growth and metastasis, there is considerable interest in developing therapies that target these reactives. This study investigates the effects of some active substances from the micro-immunotherapy (MI) medicine 2LMIREG(®) on mitochondrial metabolism parameters in two CRC-derived cell lines. HT-29 and the metastasis-derived SW620 cell lines, which heavily rely on ROS for proliferation, were used to evaluate the effects of the tested active substances. Cellular viability and various mitochondrial metabolism parameters were measured: ROS production, mitochondrial mass index, and mitochondrial DNA levels. In both cell lines, the tested MI formulation reduced cellular viability as well as ROS production compared to the vehicle used as a control. The treatment also appeared to increase the mitochondrial mass index without affecting mitochondrial DNA levels in the two CRC models. Altogether, these preliminary results report for the first time the mitochondria-related effects of some actives from 2LMIREG(®) in two CRC cell models and open perspectives for further in-depth metabolism-based studies.